Market Intelligence, Clinical Progress, and High-Purity Reagents for Gout and Hyperuricemia Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for XDH drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | XDH Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 or Insect cell expressed to preserve structural integrity. |
View XDH Products |
| Gene Delivery | XDH Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View XDH Products |
| Benchmark Ab | Anti-XDH Recombinant Antibody Recombinant positive control antibody for Western Blot, ELISA, and IP assays. |
View XDH Products |
| Validator | XDH siRNA Set Target-specific siRNA pool for gene knockdown and target specificity verification in cell-based assays. |
View XDH Products |
| Related Target A | URAT1 Urate Transporter 1; key target for dual-acting XDH inhibitors/URAT1 blockers to maximize uric acid reduction. |
View URAT1 Products |
| Related Target B | GLUT9 Glucose Transporter 9; essential basolateral urate transporter involved in renal uric acid reabsorption. |
View GLUT9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity Screening against Aldehyde Oxidase (AOX1) | High-purity recombinant XDH and AOX1 proteins strictly verified by mass spectrometry to eliminate cross-contamination. |
| Species Cross-Reactivity Profiling | Human, Mouse, and Rat ortholog XDH proteins available with >95% purity for robust translational screening. |
| Lack of Validated Screening Controls | Sequence-verified clinical benchmark antibodies and high-potency siRNA sets included for assay validation. |
| Protein Stability & Activity Consistency | Endotoxin-controlled, native-like glycosylation, and optimized buffer formulation to ensure shelf-life and assay reproducibility. |
Live XDH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for XDH (Xanthine Dehydrogenase/Oxidase) therapeutics is intensifying, with major players shifting focus from traditional systemic small-molecule inhibitors to tissue-selective inhibitors and dual-targeting agents. As first-generation therapies like allopurinol and febuxostat maintain clinical dominance, the next wave of R&D is targeting superior cardiovascular safety profiles and synergistic dual-action mechanisms (such as XDH/URAT1 dual inhibitors) to address refractory gout and chronic kidney disease (CKD).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Takeda, Teijin Pharma, LG Chem | Gout, Hyperuricemia, Chronic Kidney Disease | Enzymatic Selectivity Assay (Need high-purity, sequence-verified recombinant XDH and AOX1) |
| Dual-Target Inhibitors (XDH/URAT1) | AstraZeneca, Shijiazhuang Yiling | Refractory Gout, Hyperuricemia | Synergistic Assay Panels (Need concurrent availability of high-purity XDH and membrane-bound URAT1) |
| RNA Interference (siRNA) | Alnylam, Arrowhead | Cardiovascular diseases, Metabolic syndrome | Knockdown Verification (Need high-specificity XDH siRNA and target-specific qPCR/WB validators) |